Adherence to cancer surveillance guidelines varies

March 30, 2012
Adherence to cancer surveillance guidelines varies

(HealthDay) -- Insured breast cancer survivors have high rates of guideline-recommended recurrence testing and non-recommended metastatic testing, while only about half of colorectal cancer survivors undergo recommended surveillance and two-thirds receive non-recommended metastatic testing, according to a study published online March 20 in Cancer.

To determine how surveillance practices used in four distinct geographic managed care environments compared with surveillance , Ramzi G. Salloum, Ph.D., of the University of North Carolina at Chapel Hill, and colleagues conducted a study involving 6,205 insured breast cancer and 2,297 survivors, between 2000 and 2008.

Within 18 months of treatment, the researchers found that 87.2 percent of received recommended mammograms and 55.0 percent of colorectal cancer survivors received recommended colon examinations. Significantly higher rates of surveillance were seen for breast cancer survivors between 50 and 65 years of age and significantly lower rates were seen for survivors who were 75 years of age or older. Non-recommended metastatic disease testing was performed for 64.7 percent of breast and 73.3 percent of colorectal cancer survivors. Younger age and comorbidities were associated with higher rates of non-recommended metastatic disease testing for both breast and colorectal cancer survivors, and white race was also associated with increased testing for survivors.

"Although many cancer survivors appear to be receiving the minimum recommended surveillance care, a large number, regardless of age, are still not receiving minimum care recommendations, whereas others are receiving non-recommended metastatic disease testing as well as recommended care at a greater frequency than what is suggested," the authors write.

Explore further: Breast cancer survivors struggle with cognitive problems several years after treatment

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

Fighting cancer with the power of immunity

October 24, 2016

Harnessing the body's own immune system to destroy tumors is a tantalizing prospect that has yet to realize its full potential. However, a new advance from MIT may bring this strategy, known as cancer immunotherapy, closer ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.